Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

Background A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer …

Aberrant c‐Met activity has been implicated in the development of hepatocellular carcinoma
(HCC), suggesting that c‐Met inhibition may have therapeutic potential. However, clinical …

The abnormal expression of the c-Met tyrosine kinase has been linked to the proliferation of
several human cancer cell lines, including non-small-cell lung cancer (NSCLC). In this …

Exosomes are important contributors to cell–cell communication and their role as diagnostic
markers for cancer and the pathogenesis for cancer is under intensive investigation. Here …

Despite the recent introduction of new effective systemic agents, the survival of patients with
hepatocellular carcinoma (HCC) at advanced stages remains dismal. This underscores the …

Purpose This first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly
called ABBV-399, an antibody–drug conjugate of the anti–c-Met monoclonal antibody ABT …

Abstract c-Met is a prototype member of a subfamily of heterodimeric receptor tyrosine
kinases (RTKs) and is the receptor for hepatocyte growth factor (HGF). Binding of HGF to its …

The role of aberrant hepatocyte growth factor receptor (c-MET, also known as tyrosine-
protein kinase MET)/hepatocyte growth factor (HGF) signaling in cancer progression and …